*NEWS: Biotherapeutics Startup Gets NIH Grant
A biotherapeutics startup focusing on celiac disease has received a grant from the NIH’s National Institute of Allergy and Infectious Diseases.
ImmunogenX, with HQ in Newport Beach, can now conduct a Phase 2 trial for latiglutenase, an investigational drug for celiac disease, the company announced in an April 9 press release.
The study will be conducted at multiple study centers including the Mayo Clinic in Minnesota and Columbia University in NYC.
The main focus will be symptom relief in celiac patients who continue to exhibit high gluten-induced antibody levels, despite strict adherence to a gluten-free diet.
The NIH grant was awarded as part of the Small Business Innovation Research program and is notable for being a fast-track application in which both the Phase I and II work is approved, according to the company. It’s also at the highest funding level allowable, based on the application addressing a critical topic area.
Jack Syage is CEO of ImmunogenX. The company was founded in 2013.